Skip to content

Study · Non-randomized trial · n = 30 · 2000

2 results

A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.

Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Veldhuis JD

The Journal of clinical endocrinology and metabolism1 Jan 2000Cited by 65 (Europe PMC)

PMID10634385 (opens in a new tab)DOI10.1210/jcem.85.1.6316 (opens in a new tab)PepBankPUB-10634385
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In protracted critically ill patients, the GH response to GHRP‑2 was supranormal and higher in women than in men.

    In plain wordsIn patients with long critical illness, GHRP‑2 caused a higher GH response in women than in men.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH response to GHRP-2 in critically ill women versus men
    Study

    n = 30

    Comparator
    Male patients
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kgAs given in this study (human).

    Measurements

    GH response
    93 microg/L
    women
    GH response
    28 microg/L
    men

    Source sentences

    Summary
    GH responses to GHRP-2 in women (93+/-38 microg/L) were supranormal and higher (P<0.0001) than those in men (28+/-16 microg/L).
    1 context sentence
    Summary · context
    In a second study, GH responses to GHRH (1 microg/kg), GH-releasing peptide-2 (GHRP-2; 1 microg/ kg) and GHRH plus GHRP-2 (1 and 1 microg/kg) were examined in comparable, carefully matched male (n = 15) and female (n = 15) patients.

Studies that did not test the peptide alone1

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 02HumanNot a test of GHRP-2 aloneNon-randomized trialEfficacy outcome

    In protracted critically ill patients, combining GHRH with GHRP‑2 removed the gender difference in the GH response.

    In plain wordsIn patients with long critical illness, GHRH plus GHRP‑2 together gave similar GH responses in men and women.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH response to GHRH plus GHRP-2 in critically ill women versus men
    Study

    n = 30

    Comparator
    Male patients
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH response
    77 microg/L
    men
    GH response
    120 microg/L
    women

    Source sentences

    Summary
    Combining GHRH with GHRP-2 nullified this gender difference (77+/-58 in men vs. 120+/-69 microg/L in women; P = 0.4).
    1 context sentence
    Summary · context
    In a second study, GH responses to GHRH (1 microg/kg), GH-releasing peptide-2 (GHRP-2; 1 microg/ kg) and GHRH plus GHRP-2 (1 and 1 microg/kg) were examined in comparable, carefully matched male (n = 15) and female (n = 15) patients.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.